Sarcoma  >>  Halaven (eribulin mesylate)  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Halaven (eribulin mesylate) / Eisai
HAL03T, NCT03058406: A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas

Completed
N/A
256
Japan
Eribulin mesylate, Halaven Injection, E7389
Eisai Co., Ltd.
Sarcoma, Soft Tissue
11/18
11/18
ChiCTR2100053594: Efficacy and safety of eribulin monotherapy or combination therapy in Chinese adults with soft tissue sarcoma

Not yet recruiting
N/A
 
Anthracycline-based drugs ;Ifosfamide-based ;Other chemotherapy options ;Combined molecular targeted therapy ;Combination immune checkpoint inhibitor therapy
Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University, self-funded
soft tissue sarcoma (STS)
 
 

Download Options